

## Clearbridge partners with Genome.One to offer clinical-grade personal health genomics programme

- *Partnership reinforces Clearbridge's commitment as a precision healthcare provider to offer individualised and holistic solutions for future healthcare management*
- *Genome. One's comprehensive programme assesses individual's risk of developing 52 hereditary conditions, including 31 cancers, 13 heart conditions, and other conditions, together with genetic counselling and multi-language reports*

**SINGAPORE – 26 June 2018 – Clearbridge Health Limited** (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company with a focus on the delivery of precision medicine in Asia, has entered into a collaboration with Australia-based health information company, Genome.One Pty Ltd (“Genome.One”). The partnership between Clearbridge and Genome.One will enable easy access to clinical-grade quality whole genome sequencing and analysis to guide personal health management with genetic counselling in a comprehensive programme.

Under the partnership, Clearbridge clinicians will refer patients in Singapore and Hong Kong to Genome.One's GoExplore™ personal health genomics programme, which sequences and analyses patients' DNA samples to assess their risk of developing 52 hereditary conditions, including 31 cancers, 13 heart conditions, as well as several other conditions where monitoring or intervention can be of benefit. The test will also determine patients' likely response to over 220 different types of medication.

The partnership is strongly in line with Clearbridge's focus on the delivery of clinical-grade precision medicine by enabling healthcare professionals to gain better insights into management of hereditary conditions.

Genome.One is a wholly-owned subsidiary of the Garvan Institute of Medical Research, a clinically accredited provider of whole genome sequencing and analysis services. Genome.One's genetic health professionals will provide support to individuals both before and after testing via telehealth consultations to help patients understand their risks, as well as the implications for themselves and their families. Interpreters and different language reports will also be available for non-English speaking patients.

**Dr Marcel Dinger, Chief Scientific Officer, Genome.One** said, *“We are thrilled to be able to make clinically-accredited genomic testing and analysis more widely available to people outside Australia through our partnership with Clearbridge. This new layer of genomic health information can give individuals an insight into their future health risks, and empower them with valuable information to*



*help them take a more proactive approach to managing their health. This growing access to genomic information is a step towards the next generation in precision healthcare.”*

**Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge,** said, *“We are pleased to partner with Genome.One to bring clinical-grade genome sequencing and analysis to our patients in Singapore and Hong Kong. This is a ground-breaking test that will allow patients to understand their risk level in terms of hereditary conditions by analysing one’s unique genomic information and how the human body will react to a host of different medications, we are then able to provide customised and targeted preventive treatments for our patients. This partnership reinforces our commitment as a leading precision healthcare provider, to offer individualised and holistic solutions for future healthcare management.”*

-- END --

#### **About Clearbridge Health Limited**

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit [www.clearbridgehealth.com](http://www.clearbridgehealth.com)

#### **About Genome.one**

Genome.one is a pioneering health information company that is leading the way in improving access to genetic information, through clinically-accredited genomic analysis and the development of novel healthcare applications. Genome.one is a wholly-owned subsidiary of Garvan Institute of Medical Research and is enhancing the lives of patients, families and communities by enabling the future of precision healthcare.

For more information, please visit [www.genome.one](http://www.genome.one)

---

*Issued by and on behalf of Clearbridge Health Limited*

#### **August Consulting**

Tel: +65 6733 8873

Silvia Heng, [silviaheng@august.com.sg](mailto:silviaheng@august.com.sg)

Wrisney Tan, [wrisneytan@august.com.sg](mailto:wrisneytan@august.com.sg)

Zavier Ong, [zavierong@august.com.sg](mailto:zavierong@august.com.sg)



*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**").*

*The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*